FR21C1044I2 - Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire - Google Patents

Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire

Info

Publication number
FR21C1044I2
FR21C1044I2 FR21C1044C FR21C1044C FR21C1044I2 FR 21C1044 I2 FR21C1044 I2 FR 21C1044I2 FR 21C1044 C FR21C1044 C FR 21C1044C FR 21C1044 C FR21C1044 C FR 21C1044C FR 21C1044 I2 FR21C1044 I2 FR 21C1044I2
Authority
FR
France
Prior art keywords
hao1
double
composition
stranded rna
specific inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1044C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of FR21C1044I1 publication Critical patent/FR21C1044I1/fr
Application granted granted Critical
Publication of FR21C1044I2 publication Critical patent/FR21C1044I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
FR21C1044C 2013-12-27 2021-09-20 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire Active FR21C1044I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361921181P 2013-12-27 2013-12-27
US201461937838P 2014-02-10 2014-02-10
EP14874374.3A EP3087184B1 (fr) 2013-12-27 2014-12-26 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire
PCT/US2014/072410 WO2015100436A1 (fr) 2013-12-27 2014-12-26 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire

Publications (2)

Publication Number Publication Date
FR21C1044I1 FR21C1044I1 (fr) 2021-11-19
FR21C1044I2 true FR21C1044I2 (fr) 2022-09-23

Family

ID=53479713

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1044C Active FR21C1044I2 (fr) 2013-12-27 2021-09-20 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire

Country Status (19)

Country Link
US (7) US9701966B2 (fr)
EP (3) EP3892727A1 (fr)
JP (2) JP6886818B2 (fr)
AU (2) AU2014369850B2 (fr)
CA (1) CA2935220A1 (fr)
CY (1) CY1124203T1 (fr)
DK (2) DK3087184T3 (fr)
ES (2) ES2749855T3 (fr)
FR (1) FR21C1044I2 (fr)
HR (1) HRP20210612T1 (fr)
HU (2) HUE055470T2 (fr)
LT (2) LT3581654T (fr)
LU (1) LUC00218I2 (fr)
NO (1) NO2021038I1 (fr)
PL (1) PL3581654T3 (fr)
PT (1) PT3581654T (fr)
RS (1) RS61892B1 (fr)
SI (1) SI3581654T1 (fr)
WO (1) WO2015100436A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2015100436A1 (fr) 2013-12-27 2015-07-02 Dicerna Pharmaceuticals, Inc. Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016205323A1 (fr) * 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant l'hydroxyacide oxydase (glycolate oxydase, hao1) et procédés d'utilisation de ceux-ci
WO2018065303A1 (fr) * 2016-10-05 2018-04-12 Syngenta Participations Ag Procédés de conservation de l'activité biologique d'acides ribonucléiques
EP4035659A1 (fr) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes destinés à l'administration d'agents thérapeutiques
JP7337044B2 (ja) 2017-07-13 2023-09-01 アルナイラム ファーマシューティカルズ, インコーポレイテッド Hao1(ヒドロキシ酸オキシダーゼ1(グリコール酸オキシダーゼ))遺伝子発現の阻害方法
JP2021531804A (ja) * 2018-07-31 2021-11-25 インテリア セラピューティクス,インコーポレイテッド 原発性高シュウ酸尿症1型(ph1)を治療するためのヒドロキシ酸オキシダーゼ1(hao1)遺伝子編集のための組成物および方法
EP3898661A1 (fr) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Modification génétique du gène de l'hydroxyacide oxydase 1 pour le traitement de l'hyperoxalurie primaire
KR20220097442A (ko) 2019-11-01 2022-07-07 기안알엑스 사이언스 인코포레이티드 글리콜레이트 산화효소 억제제로서의 헤테로사이클릭 카르복실레이트 화합물
US20230242918A1 (en) * 2020-05-22 2023-08-03 President And Fellows Of Harvard College Interferon- inducing oligonucleotide duplexes and methods of use
KR20230118841A (ko) 2020-11-12 2023-08-14 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
EP4043018A1 (fr) 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition et procédé pour réduire les niveaux d'oxalate chez des patients en dialyse d'entretien
IL308803A (en) 2021-06-04 2024-01-01 Arbor Biotechnologies Inc Gene editing systems comprising guide RNA targeting hydroxy acid oxidase 1 (HAO1) and uses thereof
WO2023003805A1 (fr) * 2021-07-19 2023-01-26 Alnylam Pharmaceuticals, Inc. Méthodes et compositions pour traiter des sujets ayant ou ayant un risque de développer une maladie ou un trouble d'hyperoxalurie non primaire

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513207A (en) 1894-01-23 Rail-brake
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
CA2093664C (fr) 1990-10-12 2003-07-29 Fritz Eckstein Ribozymes modifies
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
PT748382E (pt) 1993-09-02 2003-03-31 Ribozyme Pharm Inc Acidos nucleicos enzimaticos contendo nao-nucleotidos
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US7678897B2 (en) * 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA
WO2006006948A2 (fr) 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1752536A4 (fr) 2004-05-11 2008-04-16 Alphagen Co Ltd Polynucleotide provoquant l'interference rna et procede de regulation d'expression genetique avec l'usage de ce dernier
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (fr) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification de molecules d'acide ribonucleique bicatenaire
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
DE102007021853A1 (de) 2007-05-10 2008-11-13 Norma Germany Gmbh Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh) 2008-12-08 2012-06-20 鸿富锦精密工业(深圳)有限公司 光伏电池
AU2009336191B2 (en) 2008-12-18 2017-08-24 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
EP2756845B1 (fr) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Procédés et compositions pour l'inhibition spécifique de KRAS par de l'ARN double brin asymétrique
CN102803955B (zh) * 2009-05-21 2015-10-21 系统生物学研究所 肝损伤的新标志物
KR102095699B1 (ko) 2011-11-18 2020-04-02 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
WO2015100436A1 (fr) 2013-12-27 2015-07-02 Dicerna Pharmaceuticals, Inc. Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))

Also Published As

Publication number Publication date
LTPA2021008I1 (fr) 2021-09-27
US20210230604A1 (en) 2021-07-29
US9701966B2 (en) 2017-07-11
JP2017502668A (ja) 2017-01-26
US20180291379A1 (en) 2018-10-11
HRP20210612T1 (hr) 2021-08-20
US11060093B2 (en) 2021-07-13
LT3581654T (lt) 2021-06-25
US10465195B2 (en) 2019-11-05
US11873493B2 (en) 2024-01-16
ES2749855T3 (es) 2020-03-24
US20150184160A1 (en) 2015-07-02
US20190194665A1 (en) 2019-06-27
DK3087184T3 (da) 2019-07-29
FR21C1044I1 (fr) 2021-11-19
SI3581654T1 (sl) 2021-08-31
CA2935220A1 (fr) 2015-07-02
ES2875558T3 (es) 2021-11-10
JP2020036603A (ja) 2020-03-12
AU2021201953A1 (en) 2021-04-29
US20170306333A1 (en) 2017-10-26
LUC00218I2 (fr) 2022-10-07
US10487330B2 (en) 2019-11-26
US20190211340A1 (en) 2019-07-11
PL3581654T3 (pl) 2021-09-13
US9828606B2 (en) 2017-11-28
NO2021038I1 (no) 2021-09-16
LTC3581654I2 (fr) 2023-07-10
AU2014369850B2 (en) 2021-04-08
EP3087184B1 (fr) 2019-07-03
RS61892B1 (sr) 2021-06-30
HUE055470T2 (hu) 2021-11-29
US10435692B2 (en) 2019-10-08
JP7109416B2 (ja) 2022-07-29
AU2014369850A1 (en) 2016-07-14
JP6886818B2 (ja) 2021-06-16
WO2015100436A1 (fr) 2015-07-02
EP3892727A1 (fr) 2021-10-13
EP3087184A1 (fr) 2016-11-02
PT3581654T (pt) 2021-06-02
EP3581654A1 (fr) 2019-12-18
EP3581654B1 (fr) 2021-03-31
DK3581654T3 (da) 2021-04-26
US20200002705A1 (en) 2020-01-02
HUS2100041I1 (hu) 2021-10-28
EP3087184A4 (fr) 2017-08-16
CY1124203T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
FR21C1044I2 (fr) Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire
IL240215A0 (en) Methods for the purification of messenger RNA
EP3134506A4 (fr) Procédés de purification de l'arn messager
GB2487632B (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EP2895609A4 (fr) Procédés et compositions pour l'inhibition spécifique de myc par arn à double brin
HK1227054A1 (zh) 利用雙鏈RNA以特異性抑制β-聯蛋白的方法和組成
EP3077511A4 (fr) Méthodes et compositions pour l'inhibition spécifique de transthyrétine (ttr) par un arn bicaténaire
EP3087036A4 (fr) Méthode de purification biologique d'eau
FR2982259B1 (fr) Procede de production d'acrylate de 2-octyle par esterification directe
BR112014010997A2 (pt) processo para o preparo de ß-glicosídeos de c-arila
FR3039063B1 (fr) Procede d'enrichissement en pongamol d'huile de karanja
BR112014009775A2 (pt) composição, método, semente e composto de fórmula 1
FR2999572B1 (fr) Procede de production d'acrylate d'alkyle.
EP2931746A4 (fr) Procédés et compositions pour l'inhibition spécifique de ckap5 par un arn à double brin
EP3017042A4 (fr) Procédé de purification d'acides nucléiques ciblés obtenus à partir d'acides nucléiques d'arrière-plan
BR112014011620A2 (pt) processo de preparação de pelo menos uma nitrila
FR3002771B1 (fr) Procede de production d'acrylate de 2-propyl heptyle par transesterefication
FR3040013B1 (fr) Procede de compactage d'une peinture anti-corrosion d'une piece de turbomachine
BR112014003169A2 (pt) processo de fundição de peças metálicas monocristalinas
FR3007036B1 (fr) Composition utile pour l'elimination d'etiquettes
BR112014008845A2 (pt) processo de tratamento anticorrosão
FR2985411B1 (fr) Procede pour favoriser l'exsudation de l'oleoresine et composition pour mettre en oeuvre ce procede
MX2014001409A (es) Metodo para tratar esquizofrenia.
FR2999175B1 (fr) Procede d'isolement de diamandoides
FR2980475B1 (fr) Procede de production d'esters acryliques